Figure 5. combination of Cripto-1 and tumor features predicts response to postoperative TACE. All patients were divided according to Cripto-1 levels within vascular invasion (A, B), lager tumor size (C, D) or liver cirrhosis (E, F). Kaplan-Meier survival estimates and log-rank tests were used to analyze the correlation of adjuvant TACE therapy and OS/TTR in different subgroups.